G
Giuliano Binetti
Researcher at Sacred Heart Hospital
Publications - 250
Citations - 13455
Giuliano Binetti is an academic researcher from Sacred Heart Hospital. The author has contributed to research in topics: Frontotemporal dementia & Dementia. The author has an hindex of 60, co-authored 234 publications receiving 11295 citations. Previous affiliations of Giuliano Binetti include Massachusetts Institute of Technology.
Papers
More filters
Journal ArticleDOI
Secretory leukocyte protease inhibitor protein regulates the penetrance of frontotemporal lobar degeneration in progranulin mutation carriers.
Roberta Ghidoni,Rosa Flocco,Anna Paterlini,Michela Glionna,Loredana Caruana,Elisa Tonoli,Giuliano Binetti,Luisa Benussi +7 more
TL;DR: The study of SLPI and its relation to progranulin suggests the existence of unexpected molecular players in progranul-associated neurodegeneration.
Journal ArticleDOI
Analysis of alpha-2-macroglobulin-2 allele as a risk factor in Alzheimer's disease.
Francesca Nicosia,Antonella Alberici,Luisa Benussi,Laura Gasparini,Roberta Ghidoni,Federica Mazzoli,Orazio Zanetti,Giovanni B. Frisoni,Cristina Geroldi,Giuliano Binetti +9 more
TL;DR: The results did not show any significant difference between A2M-2 allelic frequency or genotype frequency in the two different clinical series and in control subjects and the frequencies were not significantly different after stratification by APOE Ε4 status.
Journal ArticleDOI
Effect of the XbaI polymorphism of estrogen receptor alpha on postmenopausal gray matter
Marina Boccardi,Catia Scassellati,Roberta Ghidoni,Cristina Testa,Luisa Benussi,Matteo Bonetti,Luisella Bocchio-Chiavetto,Massimo Gennarelli,Giuliano Binetti,Giovanni B. Frisoni +9 more
TL;DR: The XbaI/X allele in ERalpha gene is associated to smaller gray matter volumes of the cerebral and cerebellar cortex, which might increase the susceptibility for senile neurodegenerative conditions, being related to smaller cerebral reserve.
Journal ArticleDOI
Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia.
Irene Rosas,Carmen Martínez,Eliecer Coto,Jordi Clarimón,Alberto Lleó,Ignacio Illán-Gala,Oriol Dols-Icardo,Barbara Borroni,Maria Rosário Almeida,Julie van der Zee,Christine Van Broeckhoven,Amalia C. Bruni,Maria Anfossi,Livia Bernardi,Raffaele Maletta,Maria Serpente,Daniela Galimberti,Elio Scarpini,Giacomina Rossi,Paola Caroppo,Luisa Benussi,Roberta Ghidoni,Giuliano Binetti,Benedetta Nacmias,Sandro Sorbi,Irene Piaceri,Silvia Bagnoli,Anna Antonell,Raquel Sánchez-Valle,Beatriz De la Casa-Fages,Francisco Grandas,Monica Diez-Fairen,Pau Pastor,Raffaele Ferrari,Ifgc,Daniel Queimaliños-Perez,Sergio Pérez-Oliveira,Victoria Alvarez,Manuel Menéndez-González +38 more
TL;DR: The results suggest that TP53, GRN, and APOE genes may act as phenotype modifiers in FTD and should be considered in future clinical trials.
Journal ArticleDOI
Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease
TL;DR: It is suggested that RV-TDP provides an effective long-term management option in patients with AD compared with oral RV-CP and further randomized, double-blind, placebo-controlled trial studies with a bigger sample size as well as healthy controls are needed to support these initial results.